Original Article
Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter Gene ABCB1
N Engl J Med 2003; 348:1442-1448April 10, 2003
- Abstract
Background
One third of patients with epilepsy have drug-resistant epilepsy, which is associated with an increased risk of death and debilitating psychosocial consequences. Because this form is resistant to multiple antiepileptic drugs, the mode of resistance must be nonspecific, involving drug-efflux transporters such as ATP-binding cassette sub-family B member 1 (ABCB1, also known as MDR1 and P-glycoprotein 170). We hypothesized that the CC genotype at the ABCB1 C3435T polymorphism, which is associated with increased expression of the protein, influences the response to antiepileptic-drug treatment.
Methods
ABCB1 3435 was genotyped in 315 patients with epilepsy, classified as drug-resistant in 200 and drug-responsive in 115, and 200 control subjects without epilepsy. Recently devised methods were used to control for population stratification, and linkage disequilibrium was calculated across the gene.
Results
As compared with patients with drug-responsive epilepsy, patients with drug-resistant epilepsy were more likely to have the CC genotype at ABCB1 3435 than the TT genotype (odds ratio, 2.66; 95 percent confidence interval, 1.32 to 5.38; P=0.006). There was no genetic stratification between the two groups of patients. The polymorphism fell within an extensive block of linkage disequilibrium spanning much or all of the gene, implying that the polymorphism may not itself be causal but rather may be linked with the causal variant.
Conclusions
These pharmacogenomic results identify a genetic factor associated with resistance to antiepileptic drugs.
Media in This Article
Table 1
Summary of Genotype and Phenotype Data.Table 2
Distribution of Alu Insertion Polymorphisms among the Patients with Drug-Resistant and Drug-Responsive Epilepsy.Article Activity
- Article
The continued occurrence of seizures despite the use of several antiepileptic drugs, even as polytherapy at maximal tolerated doses, is a major health problem and increases the risk of death from epilepsy. None of the reported associations with clinical drug resistance, such as remote symptomatic causes, early onset, multiple seizure types, and a high frequency of seizures before the initiation of treatment, provide a mechanistic explanation of the phenomenon.1-3 In addition, it is not clear why the same type of epilepsy may be drug-resistant in one person and drug-responsive in another and whether this is a pharmacogenomic phenomenon.
Drug resistance in epilepsy constitutes a true multidrug-resistance phenotype, since antiepileptic drugs act through diverse mechanisms. Most antiepileptic drugs are planar lipophilic agents and thus theoretical substrates for the ATP-binding cassette subfamily B member 1 (ABCB1) transporter (also known as MDR1 and P-glycoprotein 170), the up-regulation of which causes a multidrug-resistance phenotype in cancer cells.4 ABCB1 can transport at least four antiepileptic drugs.5 In patients with epilepsy, the multidrug-resistance phenotype is associated with increased lesional ABCB1 levels in resected brain tissue.6-11 Thus, the ABCB1 gene is an important candidate gene potentially influencing the response to antiepileptic drugs. To evaluate its involvement in drug resistance in epilepsy and explore its pharmacogenomics, we typed the ABCB1 polymorphism (C to T) at position 3435 in 315 patients with epilepsy classified as either drug-resistant or drug-responsive. The CC genotype is associated with both increased levels and increased activity of ABCB1 protein.12
Methods
Subjects
The study was approved by the joint research ethics committee of the National Hospital for Neurology and Neurosurgery and the University College London Institute of Neurology in London. All patients gave written informed consent. All patients were recruited through the same epilepsy clinic at the National Hospital for Neurology and Neurosurgery and were consecutive patients with an established clinical diagnosis of epilepsy (defined by the occurrence of two or more unprovoked seizures). Patients were eligible if they had either drug-resistant or drug-responsive epilepsy according to the following definitions and criteria. Drug resistance was defined as the occurrence of at least four seizures over the year before recruitment with trials of more than three appropriate antiepileptic drugs at maximal tolerated doses, which were established on the basis of the occurrence of clinical side effects at supramaximal doses. Where it was possible, only the recognized, more specific drugs for a syndrome were considered appropriate — for example, failure of a case of primary generalized epilepsy to respond to carbamazepine was not considered a failure for the purposes of this study.
Drug responsiveness was defined as complete freedom from seizures for at least a year, up to the date of the last follow-up visit, in patients with epilepsy treated with antiepileptic drugs. Of the patients who were invited to participate, six declined (less than 2 percent). Control subjects were 200 consecutive white patients with neurologic conditions without epilepsy who were identified from a DNA repository at the Institute of Neurology. Patients who had undergone surgical treatment for their drug-resistant epilepsy were classified as having drug-resistant disease irrespective of the outcome of surgery. All DNA was analyzed and all studies were conducted in a blinded fashion.
Genotyping at ABCB1 3435
DNA was extracted from blood samples according to standard methods. Samples from the first 262 patients and 90 controls were genotyped by Epidauros by an automated method on purified genomic DNA by a TaqMan assay specifically devised to distinguish the C3435T polymorphism of the human ABCB1 gene. The C3435T polymorphism was analyzed in samples from the remaining patients and controls in the United Kingdom by direct sequencing with use of information supplied by Epidauros. Amplified polymerase-chain-reaction (PCR) products were sequenced with the use of forward and reverse primers, the Big Dye Terminator cycle sequencing kit (Perkin Elmer), and an automated sequencer (model 377, ABI). The sequences were analyzed with use of the Sequence Navigator program (Perkin Elmer).
Genomic Control
To address the possibility that any observed differences in allele frequency between drug-resistant and drug-responsive populations might be due to an unsuspected population structure, we used a set of genetic markers with intermediate allele frequencies that were not linked to ABCB1. The markers used — polymorphic Alu insertion markers — code for variable lengths of amino acid residue repeats.
Nine polymorphic Alu insertion markers were typed on the basis of their heterozygosity and location in the human genome.13,14 Alu insertion polymorphisms were amplified by PCR in all 315 patients with epilepsy. In a 50-μl reaction, 50 to 100 ng of genomic DNA was used with 40 pmol of each primer, 2.5 mM of deoxynucleoside triphosphate, Promega Taq DNA polymerase (0.2 U), and 5 μl of Taq DNA polymerase buffer (containing 1.2 mM magnesium chloride). Samples were amplified with the following cycles: initial denaturation of 4 minutes at 95°C, then 1 minute of denaturation (95°C), 1 minute at the annealing temperature, and 1 minute of extension (72°C), repeated for 35 cycles and followed by another 10-minute period of extension (72°C). PCR products were run on agarose gels with ethidium bromide and analyzed under ultraviolet light. Two Alu markers showed significant deviation from the expected population distribution (Hardy–Weinberg equilibrium), owing to genotyping errors. Results from these markers were therefore not included in the analysis: their inclusion, however, did not change the overall results.
Calculation of Linkage Disequilibrium
Resequencing was carried out on 32 Centre d'Etude du Polymorphisme Humain trios (mother, father, and child) to genotype single-nucleotide polymorphisms in intron 2 (single-nucleotide polymorphism identity rs2888599; available at http://www.ncbi.nlm.nih.gov/SNP/), exon 12 (C1236T and C+44T),12,15 exon 21 (G2677A),16 and exon 26 (C3435T).12 PCR conditions were as follows: 15 minutes of initial denaturation at 95°C, then 35 cycles of denaturation (94°C), annealing (57°C), and extension (72°C), each for 30 seconds, and a final 10-minute period of extension (72°C). PCR was carried out with 50 ng of DNA, 2.5 mM magnesium chloride, 0.2 mM of each deoxynucleoside triphosphate, 0.5 μM of each primer, and 0.25 U of HotStarTaq polymerase (Qiagen), in a total volume of 10 μl. PCR products were sequenced in the forward direction with the Big Dye Terminator cycle sequencing kit, cleaned by standard isopropanol precipitation and analyzed with an ABI Prism automated sequencer (model 3700, Applied Biosystems).
Statistical Analysis
Allele frequencies were compared between populations with use of the chi-square test. Observed and expected allele frequencies within populations were compared by means of the Hardy–Weinberg test. Correction for genetic stratification was undertaken with use of the method of Reich and Goldstein.17 All reported P values are two-sided; a P value of less than 0.05 was considered to indicate statistical significance.
Results
As compared with the 115 patients with drug-responsive epilepsy, the 200 patients with drug-resistant epilepsy were more likely to have the CC than the TT genotype (odds ratio, 2.66; 95 percent confidence interval, 1.32 to 5.38; P=0.006) (Table 1Table 1
Summary of Genotype and Phenotype Data.). The frequency of the CT genotype did not differ significantly between the two groups. Thus, the C polymorphism was overrepresented among patients with drug-resistant epilepsy as compared with those with drug-responsive epilepsy (P=0.008). As compared with the 200 control subjects without epilepsy, patients with drug-resistant epilepsy had a higher frequency of the CC genotype and a lower frequency of the TT genotype (P=0.05). The frequencies in the drug-responsive group did not differ significantly from those of ethnically matched control subjects or published reports.15 No significant deviations from Hardy–Weinberg equilibrium were observed in either group of patients (P=0.39 for the drug-resistant group and P=0.26 for the drug-responsive group).Unexpected differences in genetic backgrounds between study groups — or population stratification — may result in spurious associations. To minimize overt population stratification, all subjects were from the same hospital clinic. In the drug-resistant and drug-responsive groups, 187 and 110 patients were white, respectively, and 13 and 5 patients were Asian, respectively (P=0.43). The association persisted when the analysis was confined to white patients (Table 1). There was no significant difference between those with drug-resistant epilepsy and those with drug-responsive epilepsy with respect to proportions of partial, generalized, or unclassified epilepsy syndromes (data not shown).
To determine whether drug-resistant and drug-responsive groups might be covertly stratified, we analyzed unlinked genomic-DNA markers (Alu insertion markers) in disparate positions across the genome. There were no significant deviations from Hardy–Weinberg equilibrium for the seven markers within either the drug-resistant or drug-responsive group (Table 2Table 2
Distribution of Alu Insertion Polymorphisms among the Patients with Drug-Resistant and Drug-Responsive Epilepsy.). The mean χ2 statistic for the comparison of allele frequencies between the drug-resistant and drug-responsive groups was 0.94, implying that the two cohorts were not significantly stratified. As an additional correction for stratification,17 we divided the observed χ2 by the maximal χ2 across unlinked sites17 consistent with the observed mean value of 0.96 and found that the ABCB1 3435 C allele remained significantly overrepresented among patients with drug-resistant epilepsy as compared with those with drug-responsive epilepsy (P<0.05).Genotyping in 32 European trios (mother, father, and child) of ABCB1 polymorphisms in intron 2 and exons 12a, 12b, 21, and 26 showed a high degree of linkage disequilibrium spanning at least between 12a and 26 (Table 3Table 3
Pairwise Comparisons for Linkage Disequilibrium among Five Single-Nucleotide–Polymorphism Loci in ABCB1.). The linkage disequilibrium may also extend upstream of exon 12, but the marker upstream of exon 12 was not sufficiently polymorphic to estimate the level of association. A simple pattern of groupings of single-nucleotide polymorphisms, or haplotype, was observed, in which five common haplotypes accounted for 88.5 percent of parental chromosomes for which complete phase information was available (haplotypes A, B, C, D, and E) (Table 4Table 4
Haplotypes of Five Single-Nucleotide–Polymorphism Loci in ABCB1.).Discussion
A role for ABCB1 in resistance to treatment of epilepsy has biologic plausibility. ABCB1 contributes to drug resistance in other diseases, including many forms of cancer,19 rheumatoid arthritis,20 and inflammatory bowel disease.21 The postulated role of a gene product in disease pathophysiology may be supported by the demonstration that polymorphisms in the encoding gene can influence that role. In whites, the ABCB1 3435 TT genotype is associated with low levels of ABCB1 in enterocytes,12 CD56+ natural killer cells,22 and peripheral-blood mononuclear cells.23 In comparison to the CC genotype, the TT genotype is also associated with functional restriction, being associated with higher plasma levels of the substrate digoxin.12 Results from other studies are conflicting: one suggested that the TT genotype is associated with increased ABCB1 levels and decreased plasma levels of the substrate fexofenadine in white American and black American subjects,24 whereas no difference in plasma fexofenadine levels was seen among white German subjects.25 We have demonstrated that the C3435T polymorphism in ABCB1 is associated with drug resistance in epilepsy, irrespective of the type of epilepsy or antiepileptic drug used.
Although the association with variation in the ABCB1 gene is strong, recent evidence that the human genome is structured in blocks of linkage disequilibrium26 and the fact that this well-known C3435T polymorphism is silent raise the possibility that the polymorphism is not itself causal but rather in linkage disequilibrium with the causal variant. Our data show evidence of linkage disequilibrium extending from at least exon 26 to exon 12, and possibly farther. Consistent with other recent evidence, we also showed that the studied region of the ABCB1 gene has a simple haplotype structure, involving five common haplotypes. These common haplotypes formed a consistent network compatible with a process of mutation without recombination (although the rare haplotypes displayed inconsistencies that could have arisen from rare recombination events). Thus, the low r2 values between some single-nucleotide polymorphisms reported in Table 3 do not indicate increased levels of recombination but rather different mutational clades, or groups. This implies that there could be many polymorphisms included within this block of linkage disequilibrium that have high r2 with the C3435T polymorphism, if they occurred in a similar part of the genealogy as the C3435T polymorphism. Thus, it may be possible to obtain a reliable clinical prediction of drug resistance without identifying the causal variant, but the possibility that there may be different patterns of association in different populations means that care may be necessary in applying such predictors to heterogeneous populations.
In fact, the extensive linkage disequilibrium across ABCB1 illustrates an analytic disadvantage of the block structure of linkage disequilibrium in the human genome26: association data may not provide precise information about the location of the causal variant.27 The final identification of the causal site may require detailed functional analyses. We note, however, that ABCB1 may be unusual in this regard, since it has an intermediate phenotype of high prevalence that could help pinpoint the causal variant. For example, although there is a high level of linkage disequilibrium across the gene, some of the rare haplotypes involving C3435T appear to have been generated by recombination. Thus, if association is incomplete, assessment of ABCB1 levels in persons with rare recombinant haplotypes may help pinpoint the variant responsible for altered expression. Such an assessment could be undertaken in resected brain tissue from patients with epilepsy.
There is mechanistic plausibility for the observed association between ABCB1 and drug-resistant epilepsy. The fluorescence of rhodamine allows quantitative determination of alterations in its intracellular retention caused by changes in the activity of ABCB1, for which it is a substrate. By comparing the intracellular retention of rhodamine under various controlled conditions, Hitzl et al. determined the influence of the C3435T polymorphism on ABCB1 transport.22 In peripheral-blood CD56+ leukocytes from volunteers, they demonstrated reduced rhodamine retention, a marker of increased ABCB1 drug transport, in leukocytes from subjects with the CC genotype, as compared with subjects with the TT genotype. Leukocytes from subjects with the CT genotype had intermediate function, providing evidence of the existence of a nucleotide-sequence–dependent level of ABCB1 function in these subjects. These findings were subsequently confirmed.24 Leukocyte levels of ABCB1 messenger RNA showed a similar trend; the highest levels were in subjects with the CC genotype and the lowest levels in subjects with the TT genotype. Rhodamine transport is a robust marker of the drug-transport capacity of ABCB1.28 These findings show that the C3435T polymorphism is truly linked to the drug-transport capacity of ABCB1 and provide an underlying mechanism.
The site of action of the observed association is likely to be within brain parenchyma. ABCB1 is present in the blood–brain barrier, and ABCB1-knockout mice have higher brain levels of ABCB1 substrates than do wild-type mice.29 Although the CC genotype was weakly associated with reduced serum levels of phenytoin, an ABCB1-substrate antiepileptic drug, in Turkish subjects,30 all our patients with drug-resistant epilepsy had received their own individual maximal tolerated doses of antiepileptic drugs. Thus, it would seem unlikely that polymorphisms in genes encoding drug-metabolizing proteins could explain our results; no such polymorphisms have yet been correlated strongly with drug-resistant epilepsy. In addition, overexpression of ABCB1 by parenchymal glial cells in the brain, which effectively constitutes a second blood–brain barrier, has been identified in resected specimens from subjects with drug-resistant epilepsy and is confined to the epileptogenic region.9 The majority (80 percent) of such surgically treated subjects become seizure-free after lesional resection, even with reduced antiepileptic-drug dosage, suggesting that localized overexpression within the epileptogenic region of the brain is more important than expression elsewhere, such as the duodenum. In mice, systemic pharmacologic inhibition of ABCB1 leads to increased levels of the ABCB1 substrate nelfinavir in brain, with only small changes in plasma levels.31
Our data show that the drug-resistant phenotype in epilepsy is associated with the ABCB1 3435 polymorphism. Although the patients with drug-resistant epilepsy and those with drug-responsive epilepsy were not stratified, all were seen at one referral center and thus were not random patients. Therefore, we cannot infer from these data the probability of resistance related to ABCB1 genotype in the general population of patients with epilepsy. Within the patient base studied, however, the probability of resistance is 75.3 percent for the CC genotype and 53.4 percent for the TT genotype. Therefore, genetic factors other than ABCB1 or environmental factors (or both) must also contribute to the response. Probably not all antiepileptic drugs are ABCB1 substrates, since some, such as vigabatrin, are not lipophilic planar molecules. Indeed, drug resistance in epilepsy is most likely multifactorial, compounded by unidentified mechanisms.
Our results suggest new avenues for early molecular prediction of drug resistance in patients with epilepsy. Use of antiepileptic drugs that are not ABCB1 substrates, inhibition of ABCB1,32 or the development of drugs that can evade ABCB1 might improve the efficacy of treatment in some patients with drug-resistant epilepsy.
Supported by a program grant from the Medical Research Council; a grant from the Brain Research Trust, United Kingdom; a grant from the German Federal Ministry of Education and Science (01GG9846); and a Royal Society–Wolfson Research Merit Award (to Dr. Goldstein).
Dr. Weale reports holding equity interests in Genostics.
We are indebted to the participating patients and physicians and to Drs. P. Abou-Sleiman, P. Dixon, M. Sweeney, N. Khan, and J. Wilson.
Source Information
From the Departments of Molecular Pathogenesis (A. Siddiqui, N.W.W.) and Clinical and Experimental Epilepsy (A. Siddiqui, S.M.S.), Institute of Neurology, and the Department of Biology (A. Smith, D.B.G.), University College London, London; Genostics, London (M.E.W.); the Pharmacogenetics Laboratory, Epidauros Biotechnology, Bernried, Germany (R.K., U.B.); and the National Neurological Institute, Singapore (M.E.W., D.B.G., N.W.W.).
Address reprint requests to Dr. Sisodiya at the Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London WC1N 3BG, United Kingdom, or at s.sisodiya@ion.ucl.ac.uk.
- References
References
1
Casetta I ,Granieri E ,Monetti VC , et al. Early predictors of intractability in childhood epilepsy: a community-based case-control study in Copparo, Italy. Acta Neurol Scand 1999;99:329-333
CrossRef | Web of Science | Medline2
Gelisse P ,Genton P ,Thomas P ,Rey M ,Samuelian JC ,Dravet C . Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001;70:240-243
CrossRef | Web of Science | Medline3
MacDonald BK ,Johnson AL ,Goodridge DM ,Cockerell OC ,Sander JW ,Shorvon SD . Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000;48:833-841[Erratum, Ann Neurol 2001;49:547, 50:830.]
CrossRef | Web of Science | Medline4
Ling V . Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40:Suppl:S3-S8
CrossRef | Web of Science | Medline5
Loscher W ,Potschka H . Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14
CrossRef | Web of Science | Medline6
Tishler DM ,Weinberg KI ,Hinton DR ,Barbaro N ,Annett GM ,Raffel C . MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6
CrossRef | Web of Science | Medline7
Sisodiya SM ,Heffernan J ,Squier MV . Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999;10:3437-3441
CrossRef | Web of Science | Medline8
Sisodiya SM ,Lin W-R ,Squier MV ,Thom M . Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357:42-43
CrossRef | Web of Science | Medline9
Sisodiya SM ,Lin WR ,Harding BN ,Squier MV ,Thom M . Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31
CrossRef | Web of Science | Medline10
Lazarowski A ,Sevlever G ,Taratuto A ,Massaro M ,Rabinowicz A . Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999;21:731-734
CrossRef | Web of Science | Medline11
Dombrowski SM ,Desai SY ,Marroni M , et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-1506
CrossRef | Web of Science | Medline12
Hoffmeyer S ,Burk O ,von Richter O , et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-3478
CrossRef | Web of Science | Medline13
Roy-Engel AM ,Carroll ML ,Vogel E , et al. Alu insertion polymorphisms for the study of human genomic diversity. Genetics 2001;159:279-290
Web of Science | Medline14
Carroll ML ,Roy-Engel AM ,Nguyen SV , et al. Large-scale analysis of the Alu Ya5 and Yb8 subfamilies and their contribution to human genomic diversity. J Mol Biol 2001;311:17-40
CrossRef | Web of Science | Medline15
Cascorbi I ,Gerloff T ,Johne A , et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-174
CrossRef | Web of Science | Medline16
Tanabe M ,Ieiri I ,Nagata N , et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-1143
Web of Science | Medline17
Reich DE ,Goldstein DB . Detecting association in a case-control study while correcting for population stratification. Genet Epidemiol 2001;20:4-16
CrossRef | Web of Science | Medline18
Weir BS. Genetic-data analysis II: methods for discrete population genetic data. Sunderland, Mass.: Sinauer, 1996.
19
Gottesman MM ,Fojo T ,Bates SE . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58
CrossRef | Web of Science | Medline20
Llorente L ,Richaud-Patin Y ,Diaz-Borjon A , et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. I. Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000;67:30-39
Web of Science | Medline21
Farrell RJ ,Murphy A ,Long A , et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-288
CrossRef | Web of Science | Medline22
Hitzl M ,Drescher S ,van der Kuip H , et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-298
CrossRef | Medline23
Fellay J ,Marzolini C ,Meaden ER , et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-36
CrossRef | Web of Science | Medline24
Drescher S ,Schaeffeler E ,Hitzl M , et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534
CrossRef | Web of Science | Medline25
Kim RB ,Leake BF ,Choo EF , et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199
CrossRef | Web of Science | Medline26
Goldstein DB . Islands of linkage disequilibrium. Nat Genet 2001;29:109-111
CrossRef | Web of Science | Medline27
Daly MJ ,Rioux JD ,Schaffner SF ,Hudson TJ ,Lander ES . High-resolution haplotype structure in the human genome. Nat Genet 2001;29:229-232
CrossRef | Web of Science | Medline28
Shapiro AB ,Ling V . The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand Suppl 1998;643:227-234
Medline29
Schinkel AH . P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-194
CrossRef | Web of Science | Medline30
Kerb R ,Aynacioglu AS ,Brockmoller J , et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-210
CrossRef | Medline31
Choo EF ,Leake B ,Wandel C , et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655-660
Web of Science | Medline32
Tai HL . Technology evaluation: valspodar, Novartis AG. Curr Opin Mol Ther 2000;2:459-467
Web of Science | Medline
- Citing Articles (231)
Citing Articles
1
Shivani Ponnala, Jaideep Ray Chaudhari, Momin Abdul Jaleel, Dilnawaz Bhiladvala, Prabhakar Rao Kaipa, Undurti N. Das, Qurratulain Hasan. (2012) Role of MDR1 C3435T and GABRG2 C588T Gene Polymorphisms in Seizure Occurrence and MDR1 Effect on Anti-Epileptic Drug (Phenytoin) Absorption. Genetic Testing and Molecular Biomarkers120112065728004
CrossRef2
M.S.M. Van Breemen, E.B. Wilms, C.J. Vecht. 2012. Seizure control in brain tumors. , 381-389.
CrossRef3
Caroline F. Thorn, Susan G. Leckband, John Kelsoe, J. Steven Leeder, Daniel J. Müller, Teri E. Klein, Russ B. Altman. (2011) PharmGKB summary. Pharmacogenetics and Genomics 21:12, 906-910
CrossRef4
E. Aronica, S.M. Sisodiya, J.A. Gorter. (2011) Cerebral expression of drug transporters in epilepsy. Advanced Drug Delivery Reviews
CrossRef5
Mike Ufer, Celina von Stülpnagel, Hiltrud Muhle, Sierk Haenisch, Cornelia Remmler, Amani Majed, Herbert Plischke, Ulrich Stephani, Gerhard Kluger, Ingolf Cascorbi. (2011) Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenetics and Genomics 21:10, 624-630
CrossRef6
Tracy A Glauser. (2011) Biomarkers for antiepileptic drug response. Biomarkers in Medicine 5:5, 635-641
CrossRef7
Gianpiero L Cavalleri, Mark McCormack, Saud Alhusaini, Elijah Chaila, Norman Delanty. (2011) Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics 12:10, 1429-1447
CrossRef8
Kwan, Patrick, Schachter, Steven C., Brodie, Martin J., . (2011) Drug-Resistant Epilepsy. New England Journal of Medicine 365:10, 919-926
Full Text9
Joost Westerhout, Meindert Danhof, Elizabeth C. M. De Lange. (2011) Preclinical prediction of human brain target site concentrations: Considerations in extrapolating to the clinical setting. Journal of Pharmaceutical Sciences 100:9, 3577-3593
CrossRef10
Dong-Uk Kim, Myeong-Kyu Kim, Yong-Won Cho, Yo-Sik Kim, Won-Joo Kim, Min Goo Lee, Sung Eun Kim, Tai-Seung Nam, Ki-Hyun Cho, Young-Ok Kim, Min-Cheol Lee. (2011) Association of a synonymous GAT3 polymorphism with antiepileptic drug pharmacoresistance. Journal of Human Genetics 56:9, 640-646
CrossRef11
Chung-Pu Wu, Chia-Hung Hsieh, Yu-Shan Wu. (2011) The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy. Molecular Pharmaceutics110726160407000
CrossRef12
Mauricio Di Ianni, Alan Talevi, Eduardo A. Castro, Luis E. Bruno-Blanch. (2011) Development of a highly specific ensemble of topological models for early identification of P-glycoprotein substrates. Journal of Chemometrics 25:6, 313-322
CrossRef13
Annelies Van Dycke, Robrecht Raedt, Kristl Vonck, Paul Boon. (2011) Local delivery strategies in epilepsy; a focus on adenosine. Seizure 20:5, 376-382
CrossRef14
Zhenhua Guo, Siqi Hong, Xianqing Jin, Qing Luo, Zhigang Wang, Yi Wang. (2011) Study on the Multidrug Resistance 1 Gene Transfection Efficiency Using Adenovirus Vector Enhanced by Ultrasonic Microbubbles In Vitro. Molecular Biotechnology 48:2, 138-146
CrossRef15
Ritu Kumari, Ram Lakhan, J. Kalita, R.K. Garg, U.K. Misra, Balraj Mittal. (2011) Potential role of GABAA receptor subunit; GABRA6, GABRB2 and GABRR2 gene polymorphisms in epilepsy susceptibility and pharmacotherapy in North Indian population. Clinica Chimica Acta 412:13-14, 1244-1248
CrossRef16
Fionn E. O’Brien, Timothy G. Dinan, Brendan T. Griffin, John F. Cryan. (2011) Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings. British Journal of Pharmacologyno-no
CrossRef17
L. Alves, V. Hülsmeyer, A. Jaggy, A. Fischer, T. Leeb, M. Drögemüller. (2011) Polymorphisms in the ABCB1 Gene in Phenobarbital Responsive and Resistant Idiopathic Epileptic Border Collies. Journal of Veterinary Internal Medicine 25:3, 484-489
CrossRef18
Hongmei Meng, Guimei Guo, Jinyan Ren, Hui Zhou, Yubin Ge, Yingjie Guo. (2011) Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy & Behavior 21:1, 27-30
CrossRef19
Batoul Sadat Haerian, Kheng Seang Lim, Chong Tin Tan, Azman Ali Raymond, Zahurin Mohamed. (2011) Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics 12:5, 713-725
CrossRef20
Alberto Lazarowski, Liliana Czornyj. (2011) Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions. Drug Metabolism and Drug Interactions 26:1, 21-26
CrossRef21
Lin Dong, Rong Luo, Yu Tong, Xiaotang Cai, Meng Mao, Dan Yu. (2011) Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: An analysis in a western Chinese pediatric population. Brain Research 1391, 114-124
CrossRef22
F. Becker, F. Zimprich, S. Sisodiya, H. Lerche. (2011) Pharmakogenetik. Zeitschrift für Epileptologie 24:2, 123-127
CrossRef23
William O. Tatum. 2011. Medial Temporal Lobe Epilepsy. , 221-245.
CrossRef24
N. Viñolas, M. Provencio, N. Reguart, F. Cardenal, V. Alberola, J.M. Sánchez-Torres, F.J. Barón, M. Cobo, I. Maestu, I. Moreno, C. Mesía, A. Izquierdo, E. Felip, M. López-Brea, A. Márquez, M. Sánchez-Ronco, M. Tarón, M.C. Santarpia, R. Rosell. (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71:2, 191-198
CrossRef25
Csilla SIPEKY, Veronika CSONGEI, Luca JAROMI, Eniko SAFRANY, Anita MAASZ, Istvan TAKACS, Judit BERES, Lajos FODOR, Melinda SZABO, Bela MELEGH. (2011) Genetic Variability and Haplotype Profile of MDR1 (ABCB1) in Roma and Hungarian Population Samples with a Review of the Literature. Drug Metabolism and Pharmacokinetics 26:2, 206-215
CrossRef26
Myeong-Kyu Kim, Jason H Moore, Jong-Ki Kim, Ki-Hyun Cho, Yong-Won Cho, Yo-Sik Kim, Min-Cheol Lee, Young-Ok Kim, Min-Ho Shin. (2011) Evidence for epistatic interactions in antiepileptic drug resistance. Journal of Human Genetics 56:1, 71-76
CrossRef27
A Chan, M Pirmohamed, M Comabella. (2011) Pharmacogenomics in Neurology - Current state and future steps. Annals of Neurologyn/a-n/a
CrossRef28
Heidrun Potschka. (2010) Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics 11:10, 1427-1438
CrossRef29
E. M. Choi, M. G. Lee, S. H. Lee, K. W. Choi, S. H. Choi. (2010) Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia 65:10, 996-1000
CrossRef30
Laila Nurmohamed, Facundo Garcia-Bournissen, Russell J. Buono, Michael W. Shannon, Yaron Finkelstein. (2010) Predisposition to epilepsy-Does the ABCB1 gene play a role?. Epilepsia 51:9, 1882-1885
CrossRef31
H. Potschka. (2010) Transporterhypothese der Pharmakoresistenz von Epilepsien. Zeitschrift für Epileptologie 23:3, 152-160
CrossRef32
E. Trinka. (2010) Medikamentöse Therapieoptionen bei pharmakoresistenten Epilepsien. Zeitschrift für Epileptologie 23:3, 166-170
CrossRef33
Yida Hu, Yang Lu, Weihua Yu, Dinglie Shen, Zheng Xiao, Zhiqin Xi, Xuefeng Wang. (2010) Long-term retention rate of topiramate as initial monotherapy in Chinese patients with newly diagnosed epilepsy: A prospective, observational study. Epilepsy Research 90:3, 278-284
CrossRef34
Ortrud K. Steinlein. (2010) Gene polymorphisms and their role in epilepsy treatment and prognosis. Naunyn-Schmiedeberg's Archives of Pharmacology 382:2, 109-118
CrossRef35
B.S. Haerian, H. Roslan, A.A. Raymond, C.T. Tan, K.S. Lim, S.Z. Zulkifli, E.H.M. Mohamed, H.J. Tan, Z. Mohamed. (2010) ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure 19:6, 339-346
CrossRef36
Sandeep Grover, Mandaville Gourie-Devi, Ruchi Baghel, Sangeeta Sharma, Kiran Bala, Meena Gupta, Krishnamoorthy Narayanasamy, Binuja Varma, Meenal Gupta, Kavita Kaur, Puneet Talwar, Harpreet Kaur, Sudheer Giddaluru, Abhay Sharma, Samir K Brahmachari, Indian Genome Variation Consortium, Ritushree Kukreti. (2010) Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 11:7, 927-941
CrossRef37
Ritu Kumari, Ram Lakhan, J. Kalita, U.K. Misra, Balraj Mittal. (2010) Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population. Seizure 19:4, 237-241
CrossRef38
Ram Lakhan, J. Kalita, U.K. Misra, Ritu Kumari, Balraj Mittal. (2010) Association of intronic polymorphism rs3773364 A>G in synapsin-2 gene with idiopathic epilepsy. Synapse 64:5, 403-408
CrossRef39
Ioannis S. Vizirianakis. 2010. From Defining Bioinformatics and Pharmacogenomics to Developing Information-Based Medicine and Pharmacotyping in Health Care. .
CrossRef40
M. Blanca Sánchez, José L. Herranz, Carlos Leno, Rosa Arteaga, Agustín Oterino, Elsa M. Valdizán, José M. Nicolás, Javier Adín, Juan A. Armijo. (2010) Genetic factors associated with drug-resistance of epilepsy: Relevance of stratification by patient age and aetiology of epilepsy. Seizure 19:2, 93-101
CrossRef41
Ken-ichi Fujita, Yuichi Ando, Wataru Yamamoto, Toshimichi Miya, Hisashi Endo, Yu Sunakawa, Kazuhiro Araki, Keiji Kodama, Fumio Nagashima, Wataru Ichikawa, Masaru Narabayashi, Yuko Akiyama, Kaori Kawara, Mari Shiomi, Hiroyasu Ogata, Hiroyasu Iwasa, Yasushi Okazaki, Takashi Hirose, Yasutsuna Sasaki. (2010) Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemotherapy and Pharmacology 65:2, 251-258
CrossRef42
I Cascorbi. (2010) ABC Transporters in Drug-Refractory Epilepsy: Limited Clinical Significance of Pharmacogenetics?. Clinical Pharmacology & Therapeutics 87:1, 15-18
CrossRef43
Shuichi Yoshida, Junji Saruwatari, Lei Chen, Fang Liu, Hiroto Iwasa, Takayuki Sugawara, Sunao Kaneko, The Epilepsy Genetic Study Group Japan. (2010) Individualized Medicine for Epilepsy -Based on Genetic Information-. Epilepsy & Seizure 3:1, 163-191
CrossRef44
Sanjay Sisodiya. (2010) Genomics of drug resistance: moving ahead. Epilepsy & Seizure 3:1, 59-64
CrossRef45
Sung Eun Kim. (2010) Genetic variations and response to antiepileptic drug. Epilepsy & Seizure 3:1, 65-71
CrossRef46
N Marchi, J Gonzalez-Martinez, M-T Nguyen, T Granata, D Janigro. (2010) Transporters in Drug-Refractory Epilepsy: Clinical Significance. Clinical Pharmacology & Therapeutics 87:1, 13-15
CrossRef47
Tiziana Granata, Nicola Marchi, Erin Carlton, Chaitali Ghosh, Jorge Gonzalez-Martinez, Andreas V Alexopoulos, Damir Janigro. (2009) Management of the patient with medically refractory epilepsy. Expert Review of Neurotherapeutics 9:12, 1791-1802
CrossRef48
A Dreiseitel, B Oosterhuis, KV Vukman, P Schreier, A Oehme, S Locher, G Hajak, PG Sand. (2009) Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. British Journal of Pharmacology 158:8, 1942-1950
CrossRef49
M. Siniatchkin, M. Koepp. (2009) Neuroimaging and neurogenetics of epilepsy in humans. Neuroscience 164:1, 164-173
CrossRef50
Stephen D Turner, Dana C Crawford, Marylyn D Ritchie. (2009) Methods for optimizing statistical analyses in pharmacogenomics research. Expert Review of Clinical Pharmacology 2:5, 559-570
CrossRef51
Ram Lakhan, Ritu Kumari, Usha K. Misra, Jayanti Kalita, Sunil Pradhan, Balraj Mittal. (2009) Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. British Journal of Clinical Pharmacology 68:2, 214-220
CrossRef52
Marcelo Andrés Kauffman, Damián Consalvo, Dolores Gonzalez-Morón, Florencia Aguirre, Luciana D’Alessio, Silvia Kochen. (2009) Serotonin transporter gene variation and refractory mesial temporal epilepsy with hippocampal sclerosis. Epilepsy Research 85:2-3, 231-234
CrossRef53
Giorgio Consoli, Marianna Lastella, Antonio Ciapparelli, Mario Catena Dell’Osso, Laura Ciofi, Emanuele Guidotti, Romano Danesi, Liliana Dell’Osso, Mario Del Tacca, Antonello Di Paolo. (2009) ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 10:8, 1267-1276
CrossRef54
Celina von Stülpnagel, Herbert Plischke, Peter Zill, Christine Bäumel, Rainer Spiegel, Rudolf Gruber, Gerhard Kluger. (2009) Letter: Lack of association between MDR1 polymorphisms and pharmacoresistance to anticonvulsive drugs in patients with childhood-onset epilepsy. Epilepsia 50:7, 1835-1837
CrossRef55
Cassandra Szoeke, Graeme J. Sills, Patrick Kwan, Slave Petrovski, Mark Newton, Nikolas Hitiris, Larry Baum, Samuel F. Berkovic, Martin J. Brodie, Leslie J. Sheffield, Terence J. O’Brien. (2009) Multidrug-resistant genotype ( ABCB1 ) and seizure recurrence in newly treated epilepsy: Data from international pharmacogenetic cohorts. Epilepsia 50:7, 1689-1696
CrossRef56
Ming-Sheng Ma, Ying-Xue Ding, Wang Ying, Fang Fang, Chang-Hong Ding, Li-Ping Zou. (2009) Effectiveness of the First Antiepileptic Drug in the Treatment of Pediatric Epilepsy. Pediatric Neurology 41:1, 22-26
CrossRef57
Dalia Kasperavičiūtė, Sanjay M Sisodiya. (2009) Epilepsy pharmacogenetics. Pharmacogenomics 10:5, 817-836
CrossRef58
Wolfgang Löscher, Norman Delanty. (2009) MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharmacogenomics 10:5, 711-713
CrossRef59
Tony Dadd, Michael E. Weale, Cathryn M. Lewis. (2009) A critical evaluation of genomic control methods for genetic association studies. Genetic Epidemiology 33:4, 290-298
CrossRef60
Patrick Kwan, Virginia Wong, Ping Wing Ng, Colin Hiu Tung Lui, Ngai Chuen Sin, Wai Sang Poon, Ho Keung Ng, Ka Sing Wong, Larry Baum. (2009) Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics 10:5, 723-732
CrossRef61
Mike Ufer, Igor Mosyagin, Hiltrud Muhle, Thies Jacobsen, Sierk Haenisch, Robert Häsler, Frank Faltraco, Cornelia Remmler, Sarah von Spiczak, Heyo K. Kroemer, Uwe Runge, Rainer Boor, Ulrich Stephani, Ingolf Cascorbi. (2009) Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenetics and Genomics 19:5, 353-362
CrossRef62
Sanjay M Sisodiya, Carla Marini. (2009) Genetics of antiepileptic drug resistance. Current Opinion in Neurology 22:2, 150-156
CrossRef63
Facundo Garcia Bournissen, Myla E. Moretti, David N. Juurlink, Gideon Koren, Mugabe Walker, Yaron Finkelstein. (2009) Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: A meta-analysis. Epilepsia 50:4, 898-903
CrossRef64
Dong Wook Kim, Sang Kun Lee, Kon Chu, In-Jin Jang, Kyung-Sang Yu, Joo-Youn Cho, Seon-Jeong Kim. (2009) Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Research 84:1, 86-90
CrossRef65
Slavé Petrovski, Cassandra E. Szoeke, Leslie J. Sheffield, Wendyl DʼSouza, Richard M. Huggins, Terence J. OʼBrien. (2009) Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases. Pharmacogenetics and Genomics 19:2, 147-152
CrossRef66
Saadi Abdul VAHAB, Supratim SEN, Nivedita RAVINDRAN, Sridevi MONY, Anila MATHEW, Neetha VIJAYAN, Geetha NAYAK, Nalini BHASKARANAND, Moinak BANERJEE, Kapaettu SATYAMOORTHY. (2009) Analysis of Genotype and Haplotype Effects of ABCB1 (MDR1) Polymorphisms in the Risk of Medically Refractory Epilepsy in an Indian Population. Drug Metabolism and Pharmacokinetics 24:3, 255-260
CrossRef67
Sin-Young Jang, Myeong-Kyu Kim, Kee-Ra Lee, Man-Seok Park, Byeong-Chae Kim, Ki-Hyun Cho, Min-Cheol Lee, Yo-Sik Kim. (2009) Gene-to-Gene Interaction between Sodium Channel-Related Genes in Determining the Risk of Antiepileptic Drug Resistance. Journal of Korean Medical Science 24:1, 62
CrossRef68
R. Lakhan, U.K. Misra, J. Kalita, S. Pradhan, N.J. Gogtay, M.K. Singh, B. Mittal. (2009) No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy & Behavior 14:1, 78-82
CrossRef69
Garima Juyal, Vandana Midha, Devendra Amre, Ajit Sood, Ernest Seidman, B.K. Thelma. (2009) Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenetics and Genomics 19:1, 77-85
CrossRef70
Wolfgang Löscher, Ulrich Klotz, Fritz Zimprich, Dieter Schmidt. (2009) The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50:1, 1-23
CrossRef71
Günfer Turgut, Mehmet Baştemir, Sebahat Turgut, Fulya Akın, Raziye Kursunluoglu, Bünyamin Kaptanoğlu. (2008) P-glycoprotein polymorphism in hypo- and hyper-thyroidism patients. Molecular Biology Reports 35:4, 693-698
CrossRef72
John R. Hughes. (2008) One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurological Research 30:9, 920-925
CrossRef73
Marie Westerlund, Andrea Carmine Belin, Lars Olson, Dagmar Galter. (2008) Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell and Tissue Research 334:2, 179-185
CrossRef74
I. Tachmazidou, T. Andrew, C. J. Verzilli, M. R. Johnson, M. De Iorio. (2008) Bayesian survival analysis in genetic association studies. Bioinformatics 24:18, 2030-2036
CrossRef75
Igor Mosyagin, Uwe Runge, Henry W. Schroeder, Eike Dazert, Silke Vogelgesang, Werner Siegmund, Rolf W. Warzok, Ingolf Cascorbi. (2008) Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 49:9, 1555-1561
CrossRef76
Malin Alenius, Mia Wadelius, Marja-Liisa Dahl, Per Hartvig, Leif Lindström, Margareta Hammarlund-Udenaes. (2008) Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of Psychiatric Research 42:11, 884-893
CrossRef77
Silvio Basic, Sanja Hajnsek, Nada Bozina, Igor Filipcic, Davor Sporis, Damir Mislov, Ana Posavec. (2008) The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood–brain barrier in patients with generalized epilepsy. Seizure 17:6, 524-530
CrossRef78
Sunao Kaneko, Shuichi Yoshida, Kazuaki Kanai, Norio Yasui-Furukori, Hiroto Iwasa. (2008) Development of individualized medicine for epilepsy based on genetic information. Expert Review of Clinical Pharmacology 1:5, 661-681
CrossRef79
Alma Mihaljevic Peles, Nada Bozina, Marina Sagud, Martina Rojnic Kuzman, Mila Lovric. (2008) MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:6, 1439-1444
CrossRef80
Umit Yasar, Melih O. Babaoglu, Atila Bozkurt. (2008) Disposition of a CYP2C9 Phenotyping Agent, Losartan, Is Not Influenced by the Common 3435C > T Variation of the Drug Transporter Gene ABCB1 ( MDR1 ). Basic & Clinical Pharmacology & Toxicology 103:2, 176-179
CrossRef81
Philip N. Patsalos, David J. Berry, Blaise F. D. Bourgeois, James C. Cloyd, Tracy A. Glauser, Svein I. Johannessen, Ilo E. Leppik, Torbjrn Tomson, Emilio Perucca. (2008) Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:7, 1239-1276
CrossRef82
Nese Dericioglu, Melih O. Babaoglu, Umit Yasar, I. Burak Bal, Atila Bozkurt, Serap Saygi. (2008) Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene. Epilepsy Research 80:1, 42-46
CrossRef83
DAN HURLEY. (2008) New Variant of Serotonin Transporter Gene Said To Improve Prediction of Resistance to Antiepileptics. Neurology Today 8:12, 19-20
CrossRef84
Dennis J. Dlugos, Russell J. Buono, Thomas N. Ferraro. (2008) Defining the Role of Anti-Epileptic Pharmacogenetics in Psychiatric Drug Therapy. Psychiatric Annals 38:6, 389-393
CrossRef85
M.W. Mann, G. Pons. (2008) La pharmacorésistance des épilepsies partielles : épidémiologie, mécanismes, pharmacogénétique, perspectives thérapeutiques. Neurochirurgie 54:3, 259-264
CrossRef86
Takayuki Seo, Takateru Ishitsu, Kentaro Oniki, Tomohide Abe, Tsuyoshi Shuto, Kazuko Nakagawa. (2008) ABCC2 haplotype is not associated with drug-resistant epilepsy. Journal of Pharmacy and Pharmacology 60:5, 631-635
CrossRef87
Chin-Chuan Hung, Chih-Chuan Chen, Chun-Jung Lin, Horng-Huei Liou. (2008) Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenetics and Genomics 18:5, 390-402
CrossRef88
Kristian Linnet, Thomas Broeng Ejsing. (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. European Neuropsychopharmacology 18:3, 157-169
CrossRef89
Chantal Depondt. (2008) Pharmacogenetics in epilepsy treatment: sense or nonsense?. Personalized Medicine 5:2, 123-131
CrossRef90
Galo Peralta, María Blanca Sánchez, Santiago Echevarría, Elsa María Valdizán, Juan Antonio Armijo. (2008) Glucoproteína P e infección por el virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica 26:3, 150-159
CrossRef91
Frances J Sharom. (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9:1, 105-127
CrossRef92
Kazuya MAEDA, Yuichi SUGIYAMA. (2008) Impact of Genetic Polymorphisms of Transporters on the Pharmacokinetic, Pharmacodynamic and Toxicological Properties of Anionic Drugs. Drug Metabolism and Pharmacokinetics 23:4, 223-235
CrossRef93
Gulay Oner Ozgon, Nerses Bebek, Gunay Gul, Naci Cine. (2008) Association of MDR1 (C3435T) Polymorphism and Resistance to Carbamazepine in Epileptic Patients from Turkey. European Neurology 59:1-2, 67-70
CrossRef94
Nada Bozina, Martina Rojnic Kuzman, Vesna Medved, Nikolina Jovanovic, Jadranka Sertic, Ljubomir Hotujac. (2008) Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. Journal of Psychiatric Research 42:2, 89-97
CrossRef95
Guy D Leschziner, Andrea L Jorgensen, Toby Andrew, Paula R Williamson, Anthony G Marson, Alison J Coffey, Claire Middleditch, David J Balding, Jane Rogers, David R Bentley, David Chadwick, Michael R Johnson, Munir Pirmohamed. (2007) The association between polymorphisms in RLIP76 and drug response in epilepsy. Pharmacogenomics 8:12, 1715-1722
CrossRef96
Sanjay M. Sisodiya, David B. Goldstein. (2007) Drug resistance in epilepsy: More twists in the tale. Epilepsia 48:12, 2369-2370
CrossRef97
Wolfgang Löscher, Graeme J. Sills. (2007) Drug resistance in epilepsy: Why is a simple explanation not enough?. Epilepsia 48:12, 2370-2372
CrossRef98
Juan Carlos Sánchez Álvarez, Pedro J. Serrano Castro, José María Serratosa Fernández. (2007) Clinical Implications of Mechanisms of Resistance to Antiepileptic Drugs. The Neurologist 13:Supplement 1, S38-S46
CrossRef99
Ivan O. Edafiogho, Samuel B. Kombian, Kethireddy V.V. Ananthalakshmi, Noha N. Salama, Natalie D. Eddington, Tiffany L. Wilson, Mariano S. Alexander, Patrice L. Jackson, Clive D. Hanson, K.R. Scott. (2007) Enaminones: Exploring additional therapeutic activities. Journal of Pharmaceutical Sciences 96:10, 2509-2531
CrossRef100
Chadwick L. West, Katrina L. Mealey. (2007) Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. American Journal of Veterinary Research 68:10, 1106-1110
CrossRef101
Tina Shih, Daniel Lowenstein. (2007) Pharmacoresistant epilepsy: if at first you don't succeed…. Annals of Neurology 62:4, 311-313
CrossRef102
Chin-Chuan Hung, John Jen Tai, Pi-Ju Kao, Min-Shung Lin, Horng-Huei Liou. (2007) Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 8:9, 1151-1158
CrossRef103
Oliver Langer, Martin Bauer, Alexander Hammers, Rudolf Karch, Ekaterina Pataraia, Matthias J. Koepp, Aiman Abrahim, Gert Luurtsema, Martin Brunner, Raute Sunder-Plassmann, Friedrich Zimprich, Christian Joukhadar, Stephan Gentzsch, Robert Dudczak, Kurt Kletter, Markus Müller, Christoph Baumgartner. (2007) Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R -[ 11 C]verapamil. Epilepsia 48:9, 1774-1784
CrossRef104
Patrick Kwan, Larry Baum, Virginia Wong, Ping Wing Ng, Colin HT Lui, Ngai Chuen Sin, Andrew C.F. Hui, Evelyn Yu, Lawrence K.S. Wong. (2007) Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy & Behavior 11:1, 112-117
CrossRef105
Haijian Wang, Keyue Ding, Yang Zhang, Li Jin, Iftikhar J. Kullo, Fuchu He. (2007) Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenetics and Genomics 17:8, 667-678
CrossRef106
DIANE E. ATKINSON, SOPHIE BRICE-BENNETT, STEPHEN W. D???SOUZA. (2007) Antiepileptic Medication During Pregnancy: Does Fetal Genotype Affect Outcome?. Pediatric Research 62:2, 120-127
CrossRef107
Neil Macdonald, Alex Gledhill. (2007) Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Archives of Toxicology 81:8, 553-563
CrossRef108
Sarah K Tate, Sanjay M Sisodiya. (2007) Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opinion on Pharmacotherapy 8:10, 1441-1449
CrossRef109
G D Leschziner, T Andrew, M Pirmohamed, M R Johnson. (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. The Pharmacogenomics Journal 7:3, 154-179
CrossRef110
Sanjay Sisodiya, Maria Thom. (2007) Response to Janigro et al.. Epilepsia 48:6, 1219-1220
CrossRef111
Sanjay Sisodiya. (2007) Etiology and management of refractory epilepsies. Nature Clinical Practice Neurology 3:6, 320-330
CrossRef112
Abdel-Hameed I Mohammed Ebid, Mona M M Ahmed, Samah A Mohammed. (2007) Therapeutic Drug Monitoring and Clinical Outcomes in Epileptic Egyptian Patients: A Gene Polymorphism Perspective Study. Therapeutic Drug Monitoring 29:3, 305-312
CrossRef113
Samuel Parry, Jian Zhang. (2007) Multidrug resistance proteins affect drug transmission across the placenta. American Journal of Obstetrics and Gynecology 196:5, 476.e1-476.e6
CrossRef114
Sanjeev V Kothare, Joseph Kaleyias. (2007) The adverse effects of antiepileptic drugs in children. Expert Opinion on Drug Safety 6:3, 251-265
CrossRef115
Zhuzhu Li, Qingxiu Li, Sindee Simon, Necip Guven, Karin Borges, Bi-Botti C. Youan. (2007) Formulation of spray-dried phenytoin loaded poly(ɛ-caprolactone) microcarrier intended for brain delivery to treat epilepsy. Journal of Pharmaceutical Sciences 96:5, 1018-1030
CrossRef116
Melanie SM van Breemen, Erik B Wilms, Charles J Vecht. (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. The Lancet Neurology 6:5, 421-430
CrossRef117
C. Simon, B. Stieger, G. A. Kullak-Ublick, M. Fried, S. Mueller, J.-M. Fritschy, H.G. Wieser, C. Pauli-Magnus. (2007) Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurologica Scandinavica 115:4, 232-242
CrossRef118
Nicole Soranzo, Libusha Kelly, Lillian Martinian, Mari-Wyn Burley, Maria Thom, Andrej Sali, Deanna L. Kroetz, David B. Goldstein, Sanjay M. Sisodiya. (2007) Lack of Support for a Role for RLIP76 (RALBP1) in Response to Treatment or Predisposition to Epilepsy. Epilepsia 48:4, 674-683
CrossRef119
Wolfgang Löscher. (2007) Drug Transporters in the Epileptic Brain. Epilepsia 48:s1, 8-13
CrossRef120
Guy D. Leschziner, Toby Andrew, John Paul Leach, David Chadwick, Alison J. Coffey, David J. Balding, David R. Bentley, Munir Pirmohamed, Michael R. Johnson. (2007) Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenetics and Genomics 17:3, 217-220
CrossRef121
Matthias J Koepp. (2007) PET tracer technology for monitoring focal epilepsies. Expert Review of Medical Devices 4:2, 191-200
CrossRef122
Amre Shahwan, Kevin Murphy, Colin Doherty, Gianpiero L Cavalleri, Clare Muckian, Pat Dicker, Mary McCarthy, Peter Kinirons, David Goldstein, Norman Delanty. (2007) The controversial association of ABCB1 polymorphisms in refractory epilepsy: An analysis of multiple SNPs in an Irish population. Epilepsy Research 73:2, 192-198
CrossRef123
Michael W Mann, Gerard Pons. (2007) Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy. CNS Drugs 21:2, 143-164
CrossRef124
Koichi Iwaki, Toshiyuki Sakaeda, Mikio Kakumoto, Tsutomu Nakamura, Chiho Komoto, Noboru Okamura, Kohshi Nishiguchi, Takashi Shiraki, Masanori Horinouchi, Katsuhiko Okumura. (2006) Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein. Journal of Pharmacy and Pharmacology 58:12, 1617-1622
CrossRef125
Ingolf Cascorbi. (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacology & Therapeutics 112:2, 457-473
CrossRef126
D J Dlugos, R J Buono, T N Ferraro. (2006) Defining the clinical role of pharmacogenetics in antiepileptic drug therapy. The Pharmacogenomics Journal 6:6, 357-359
CrossRef127
Cordula Baars, Wolfgang Löscher, Tosso Leeb, Albert Becker, Heidrun Potschka. (2006) Polymorphic variants of the multidrug resistance gene Mdr1a and response to antiepileptic drug treatment in the kindling model of epilepsy. European Journal of Pharmacology 550:1-3, 54-61
CrossRef128
Jacqueline A. French. (2006) Refractory Epilepsy: One Size Does Not Fit All. Epilepsy Currents 6:6, 177-180
CrossRef129
Noha N. Salama, Ziping Yang, Tot Bui, Rodney J.Y. Ho. (2006) MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. Journal of Pharmaceutical Sciences 95:10, 2293-2308
CrossRef130
Orrin Devinsky, Peter Camfield. (2006) Introduction and Overview. Epilepsia 47:s1, 1-2
CrossRef131
Martin Ebinger, Manfred Uhr. (2006) ABC drug transporter at the blood–brain barrier. European Archives of Psychiatry and Clinical Neuroscience 256:5, 294-298
CrossRef132
Norbert Thuerauf, Martin Friedrich Fromm. (2006) The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. European Archives of Psychiatry and Clinical Neuroscience 256:5, 281-286
CrossRef133
Guy Leschziner, Andrea L Jorgensen, Toby Andrew, Munir Pirmohamed, Paula R Williamson, Anthony G Marson, Alison J Coffey, Claire Middleditch, Jane Rogers, David R Bentley, David W Chadwick, David J Balding, Michael R Johnson. (2006) Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. The Lancet Neurology 5:8, 668-676
CrossRef134
Chantal Depondt, Simon D Shorvon. (2006) Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications. Pharmacogenomics 7:5, 731-745
CrossRef135
Rüdiger Köhling, Massimo Avoli. (2006) Methodological approaches to exploring epileptic disorders in the human brain in vitro. Journal of Neuroscience Methods 155:1, 1-19
CrossRef136
Dong Wook Kim, Manho Kim, Sang Kun Lee, Rami Kang, Seo-Young Lee. (2006) Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15:5, 344-347
CrossRef137
Takayuki Seo, Takateru Ishitsu, Nao Ueda, Naoyuki Nakada, Keigo Yurube, Kentaro Ueda, Kazuko Nakagawa. (2006) ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7:4, 551-561
CrossRef138
Guy Leschziner, Delilah Zabaneh, M. Pirmohamed, Andrew Owen, Jane Rogers, Alison J. Coffey, David J. Balding, David B. Bentley, Michael R. Johnson. (2006) Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenetics and Genomics 16:6, 439-450
CrossRef139
Emily Oby, Silvio Caccia, Annamaria Vezzani, Gabriel Moeddel, Kerri Hallene, Giovanna Guiso, Tamer Said, William Bingaman, Nicola Marchi, Christoph Baumgartner, Susanne Pirker, Thomas Czech, Giorgio Lo Russo, Damir Janigro. (2006) In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: Insights into the mechanisms of pharmacoresistance. Brain Research 1086:1, 201-213
CrossRef140
Melodie R. Winawer. (2006) Phenotype definition in epilepsy. Epilepsy & Behavior 8:3, 462-476
CrossRef141
John S Duncan, Josemir W Sander, Sanjay M Sisodiya, Matthew C Walker. (2006) Adult epilepsy. The Lancet 367:9516, 1087-1100
CrossRef142
Nigel CK Tan, John C Mulley, Ingrid E Scheffer. (2006) Genetic dissection of the common epilepsies. Current Opinion in Neurology 19:2, 157-163
CrossRef143
Reinhold Kerb. (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters 234:1, 4-33
CrossRef144
Patrick Kwan, Martin J Brodie. (2006) Refractory epilepsy: mechanisms and solutions. Expert Review of Neurotherapeutics 6:3, 397-406
CrossRef145
Lukas Cerveny, Petr Pavek, Jana Malakova, Frantisek Staud, Zdenek Fendrich. (2006) Lack of Interactions between Breast Cancer Resistance Protein (BCRP/ABCG2) and Selected Antiepileptic Agents. Epilepsia 47:3, 461-468
CrossRef146
Chantal Depondt. (2006) The potential of pharmacogenetics in the treatment of epilepsy. European Journal of Paediatric Neurology 10:2, 57-65
CrossRef147
H. Stefan, F. H. Lopes da Silva, W. Loscher, D. Schmidt, E. Perucca, M. J. Brodie, P. A. J. M. Boon, W. H. Theodore, S. L. Moshe. (2006) Epileptogenesis and rational therapeutic strategies. Acta Neurologica Scandinavica 113:3, 139-155
CrossRef148
Graeme J. Sills, Martin J. Brodie. (2006) Response: Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. Epilepsia 47:2, 450-450
CrossRef149
Cassandra EI Szoeke, Mark Newton, Julie M Wood, David Goldstein, Samuel F Berkovic, Terrence J OBrien, Les J Sheffield. (2006) Update on pharmacogenetics in epilepsy: a brief review. The Lancet Neurology 5:2, 189-196
CrossRef150
Silvio Basic, Sanja Hajnsek, Zdravka Poljakovic, Marela Basic. (2006) Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. Epilepsia 47:2, 449-449
CrossRef151
Thomas N Ferraro, Dennis J Dlugos, Russell J Buono. (2006) Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. Pharmacogenomics 7:1, 89-103
CrossRef152
Elena Urcelay, Juan L Mendoza, M Carmen Martín, Ana Mas, Alfonso Martínez, Carlos Taxonera, Miguel Fernandez-Arquero, Manuel Díaz-Rubio, Emilio G de la Concha. (2006) MDR1 gene: Susceptibility in Spanish Crohn's disease and ulcerative colitis patients. Inflammatory Bowel Diseases 12:1, 33-37
CrossRef153
David S. Jones, Roy H. Perlis. (2006) Pharmacogenetics, Race, and Psychiatry: Prospects and Challenges. Harvard Review of Psychiatry 14:2, 92-108
CrossRef154
Surajit Dey. (2006) Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert Opinion on Drug Delivery 3:1, 23-35
CrossRef155
Seema Maroo, Richard J Farrell. (2006) From SNPs to haplotypes: Unraveling the role of MDR1 in IBD. Inflammatory Bowel Diseases 12:1, 74-76
CrossRef156
Kesavan RAMASAMY, Soya SISY SAM, Adithan CHANDRASEKARAN. (2006) Allele and Genotype Frequency of MDR1 C3435T in Tamilian Population. Drug Metabolism and Pharmacokinetics 21:6, 506-508
CrossRef157
I. A. Kofiadi, D. V. Rebrikov. (2006) Methods for detecting single nucleotide polymorphisms: Allele-specific PCR and hybridization with oligonucleotide probe. Russian Journal of Genetics 42:1, 16-26
CrossRef158
Young Ok Kim, Myeong Kyu Kim, Young Jong Woo, Min Cheol Lee, Jin Hee Kim, Ki Won Park, Eun Young Kim, Young Il Roh, Chan Jong Kim. (2006) Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 15:1, 67-72
CrossRef159
Shiew-Mei Huang, Federico Goodsaid, Atiqur Rahman, Felix Frueh, Lawrence J. Lesko. (2006) Application of Pharmacogenomics in Clinical Pharmacology. Toxicology Mechanisms and Methods 16:2-3, 89-99
CrossRef160
Patrick Vallance, Trevor G Smart. (2006) The future of pharmacology. British Journal of Pharmacology 147:S1, S304-S307
CrossRef161
I. E. Scheffer. (2005) The role of genetics and ethnicity in epilepsy management. Acta Neurologica Scandinavica 112:s181, 47-51
CrossRef162
Iain AM MacPhee, Salim Fredericks, David W Holt. (2005) Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. Expert Opinion on Pharmacotherapy 6:15, 2593-2605
CrossRef163
Christian Funck-Brentano, Pierre-Yves Boëlle, Céline Verstuyft, Célia Bornert, Laurent Becquemont, Jean-Marie Poirier. (2005) Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. European Journal of Clinical Pharmacology 61:11, 821-829
CrossRef164
Sanjay M. Sisodiya. (2005) Genetics of Drug Resistance. Epilepsia 46:s10, 33-38
CrossRef165
H. L. McLeod. (2005) Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms. Clinical Infectious Diseases 41:Supplement 7, S449-S452
CrossRef166
Gwo-Tzer Ho, Daniel R Gaya, Jack Satsangi. (2005) Multidrug resistance (MDR1) gene in inflammatory bowel disease: A key player?. Inflammatory Bowel Diseases 11:11, 1013-1019
CrossRef167
Aki Sakurai, Ai Tamura, Yuko Onishi, Toshihisa Ishikawa. (2005) Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opinion on Pharmacotherapy 6:14, 2455-2473
CrossRef168
Graeme J. Sills. (2005) Pharmacogenetics of Epilepsy: One Step Forward?. Epilepsy Currents 5:6, 236-238
CrossRef169
Danxin Wang, Andrew D. Johnson, Audrey C. Papp, Deanna L. Kroetz, Wolfgang Sadée. (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenetics and Genomics 15:10, 693-704
CrossRef170
Ioannis S Vizirianakis. (2005) Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?. Pharmacogenomics 6:7, 701-711
CrossRef171
Sara Colombo, Nicole Soranzo, Margalida Rotger, Raimund Sprenger, Gabriela Bleiber, Hansjakob Furrer, Thierry Buclin, David Goldstein, Laurent Décosterd, Amalio Telenti. (2005) Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenetics and Genomics 15:9, 599-608
CrossRef172
Wolfgang Löscher, Heidrun Potschka. (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews Neuroscience 6:8, 591-602
CrossRef173
Sanjay M. Sisodiya. (2005) Genetics of drug resistance in epilepsy. Current Neurology and Neuroscience Reports 5:4, 307-311
CrossRef174
Jean-Michel Scherrmann. (2005) Expression and function of multidrug resistance transporters at the blood–brain barriers. Expert Opinion on Drug Metabolism & Toxicology 1:2, 233-246
CrossRef175
Thomas N. Ferraro, Russell J. Buono. (2005) The relationship between the pharmacology of antiepileptic drugs and human gene variation: An overview. Epilepsy & Behavior 7:1, 18-36
CrossRef176
Manfred Uhr, Martin Ebinger, Marcus C. Rosenhagen, Markus T. Grauer. (2005) The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neuroscience Letters 383:1-2, 73-76
CrossRef177
Davor Sporiš, Jadranka Sertic, Neven Henigsberg, Darija Mahovic, Nenad Bogdanovic, Tomislav Babic. (2005) Association of refractory complex partial seizures with a polymorphism of ApoE genotype. Journal of Cellular and Molecular Medicine 9:3, 698-703
CrossRef178
Barkur S. Shastry. (2005) Genetic diversity and new therapeutic concepts. Journal of Human Genetics 50:7, 321-328
CrossRef179
Nicole Soranzo, David B Goldstein, Sanjay M Sisodiya. (2005) The role of common variation in drug transporter genes in refractory epilepsy. Expert Opinion on Pharmacotherapy 6:8, 1305-1312
CrossRef180
Chin-Chuan Hung, John Jen Tai, Chun-Jung Lin, Ming-Jen Lee, Horng-Huei Liou. (2005) Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6:4, 411-417
CrossRef181
Jacques Robert, Valérie Le Morvan, Denis Smith, Philippe Pourquier, Jacques Bonnet. (2005) Predicting drug response and toxicity based on gene polymorphisms. Critical Reviews in Oncology/Hematology 54:3, 171-196
CrossRef182
Dieter Schmidt, Wolfgang Loscher. (2005) Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms. Epilepsia 46:6, 858-877
CrossRef183
Wolfgang Löscher, Heidrun Potschka. (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology 76:1, 22-76
CrossRef184
Wolfgang Loscher. (2005) How to Explain Multidrug Resistance in Epilepsy?. Epilepsy Currents 5:3, 107-112
CrossRef185
Graeme J. Sills, Rajiv Mohanraj, Elaine Butler, Sheila McCrindle, Lindsay Collier, Elaine A. Wilson, Martin J. Brodie. (2005) Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. Epilepsia 46:5, 643-647
CrossRef186
Melanie S. M. Breemen, Charles J. Vecht. (2005) Optimal seizure management in brain tumor patients. Current Neurology and Neuroscience Reports 5:3, 207-213
CrossRef187
Nigel C.K. Tan, Sarah E. Heron, Ingrid E. Scheffer, Samuel F. Berkovic, John C. Mulley. (2005) Is Variation in the GABA(B) Receptor 1 Gene Associated with Temporal Lobe Epilepsy?. Epilepsia 46:5, 778-780
CrossRef188
Erin R Lepper, Kees Nooter, Jaap Verweij, Milin R Acharya, William D Figg, Alex Sparreboom. (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6:2, 115-138
CrossRef189
Nathalie Strazielle, Jean-Fran
ois Ghersi-Egea. (2005) Factors affecting delivery of antiviral drugs to the brain. Reviews in Medical Virology 15:2, 105-133
CrossRef190
Kewal K Jain. (2005) Personalized neurology. Personalized Medicine 2:1, 15-21
CrossRef191
Patrick Kwan, Martin J. Brodie. (2005) Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy. Epilepsia 46:2, 224-235
CrossRef192
Gwo-Tzer Ho, Elaine R. Nimmo, Albert Tenesa, Janice Fennell, Hazel Drummond, Craig Mowat, Ian D. Arnott, Jack Satsangi. (2005) Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128:2, 288-296
CrossRef193
Philip H. Elsinga, N. Harry Hendrikse, Joost Bart, Aren Waarde, Willem Vaalburg. (2005) Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain. Molecular Imaging and Biology 7:1, 37-44
CrossRef194
Martin Stanulla, Elke Schäffeler, Stefan Arens, Anke Rathmann, André Schrauder, Karl Welte, a Karl Welte, Ulrich M. Zanger, Ulrich M. Zanger, Martin Schrappe, Matthias Schwab. (2005) GSTP1 and MDR1 Genotypes and Central Nervous System Relapse in Childhood Acute Lymphoblastic Leukemia. International Journal of Hematology 81:1, 39-44
CrossRef195
Toshiyuki SAKAEDA. (2005) MDR1 Genotype-related Pharmacokinetics: Fact or Fiction?. Drug Metabolism and Pharmacokinetics 20:6, 391-414
CrossRef196
Wolfgang Löscher, Heidrun Potschka. (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Neurotherapeutics 2:1, 86
CrossRef197
Wolfgang Löscher, Heidrun Potschka. (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRX 2:1, 86-98
CrossRef198
David A. Hafler, Philip L. De Jager. (2005) Opinion: Applying a new generation of genetic maps to understand human inflammatory disease. Nature Reviews Immunology 5:1, 83-91
CrossRef199
Noboru Okamura, Toshiyuki Sakaeda, Katsuhiko Okumura. (2004) Pharmacogenomics of MDR and MRP subfamilies. Personalized Medicine 1:1, 85-104
CrossRef200
Irina Serbanescu, Miguel A. Cortez, Colin McKerlie, O. Carter Snead. (2004) Refractory atypical absence seizures in rat: a two hit model. Epilepsy Research 62:1, 53-63
CrossRef201
Nigel C. K. Tan, John C. Mulley, Samuel F. Berkovic. (2004) Genetic Association Studies in Epilepsy: "The Truth Is Out There". Epilepsia 45:11, 1429-1442
CrossRef202
Sarah K Tate, David B Goldstein. (2004) Will tomorrow's medicines work for everyone?. Nature Genetics 36:11s, S34-S42
CrossRef203
P. M. Abou-Sleiman, D. G. Healy, N. W. Wood. (2004) Genetic Approaches to Solving Common Diseases. Journal of Neurology 251:10, 1169-1172
CrossRef204
K. L. Mealey. (2004) Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics 27:5, 257-264
CrossRef205
Thomas W. McAllister, Tim A. Ahles, Andrew J. Saykin, Robert J. Ferguson, Brenna C. McDonald, Lionel D. Lewis, Laura A. Flashman, C. Harker Rhodes. (2004) Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments. Current Psychiatry Reports 6:5, 364-371
CrossRef206
Patrick Kwan, Martin J. Brodie. (2004) Phenobarbital for the Treatment of Epilepsy in the 21st Century: A Critical Review. Epilepsia 45:9, 1141-1149
CrossRef207
Martin F. Fromm. (2004) Importance of P-glycoprotein at blood–tissue barriers. Trends in Pharmacological Sciences 25:8, 423-429
CrossRef208
Heidrun Potschka, Holger A. Volk, Wolfgang Löscher. (2004) Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. NeuroReport 15:10, 1657-1661
CrossRef209
Konrad Meissner, Gabriele Jedlitschky, Henriette Meyer zu Schwabedissen, Peter Dazert, Lothar Eckel, Silke Vogelgesang, Rolf W Warzok, Michael B??hm, Christian Lehmann, Michael Wendt, Ingolf Cascorbi, Heyo K Kroemer. (2004) Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14:6, 381-385
CrossRef210
Yvonne Richaud-Patin, Felipe Vega-Boada, Antonio Vidaller, Luis Llorente. (2004) Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomedicine & Pharmacotherapy 58:5, 320-324
CrossRef211
Mohammad Ali Faghihi, Salim Mottagui-Tabar, Claes Wahlestedt. (2004) Genetics of neurological disorders. Expert Review of Molecular Diagnostics 4:3, 317-332
CrossRef212
Monika Hitzl, Elke Schaeffeler, Berthold Hocher, Torsten Slowinski, Horst Halle, Michel Eichelbaum, Peter Kaufmann, Peter Fritz, Martin F Fromm, Matthias Schwab. (2004) Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14:5, 309-318
CrossRef213
Nick Patterson, Neil Hattangadi, Barton Lane, Kirk E. Lohmueller, David A. Hafler, Jorge R. Oksenberg, Stephen L. Hauser, Michael W. Smith, Stephen J. O’Brien, David Altshuler, Mark J. Daly, David Reich. (2004) Methods for High-Density Admixture Mapping of Disease Genes. The American Journal of Human Genetics 74:5, 979-1000
CrossRef214
Uwe Heinemann. (2004) Basic mechanisms of partial epilepsies. Current Opinion in Neurology 17:2, 155-159
CrossRef215
János Kappelmayer, Ágnes Simon, Flóra Kiss, Zsuzsa Hevessy. (2004) Progress in defining multidrug resistance in leukemia. Expert Review of Molecular Diagnostics 4:2, 209-217
CrossRef216
Gwo-Tzer Ho, Charlie Lees, Jack Satsangi. (2004) Pharmacogenetics and Inflammatory Bowel Disease. Inflammatory Bowel Diseases 10:2, 148-158
CrossRef217
Howard L McLeod. (2004) Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics 5:2, 139-141
CrossRef218
Simona Saponara, Masami Kawase, Anamik Shah, Noboru Motohashi, Joseph Molnar, Katalin Ugocsai, Giampietro Sgaragli, Fabio Fusi. (2004) 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility. British Journal of Pharmacology 141:3, 415-422
CrossRef219
Toshihisa Ishikawa, Akira Tsuji, Kenichi Inui, Yoshimichi Sai, Naohiko Anzai, Morimasa Wada, Hitoshi Endou, Yasuhiro Sumino. (2004) The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 5:1, 67-99
CrossRef220
Steven R. Brant, Carolien I.M. Panhuysen, Dan Nicolae, Deepthi M. Reddy, Denise K. Bonen, Reda Karaliukas, Leilei Zhang, Eric Swanson, Lisa W. Datta, Thomas Moran, Geoffrey Ravenhill, Richard H. Duerr, Jean-Paul Achkar, Amir S. Karban, Judy H. Cho. (2003) MDR1 Ala893 Polymorphism Is Associated with Inflammatory Bowel Disease. The American Journal of Human Genetics 73:6, 1282-1292
CrossRef221
Sanjay M. Sisodiya, Lillian Martinian, George L. Scheffer, Paul van der Valk, J. Helen Cross, Rik J. Scheper, Brian N. Harding, Maria Thom. (2003) Major Vault Protein, a Marker of Drug Resistance, Is Upregulated in Refractory Epilepsy. Epilepsia 44:11, 1388-1396
CrossRef222
Thomas D. Nolin, Reginald F. Frye, Gary R. Matzke. (2003) Hepatic drug metabolism and transport in patients with kidney disease. American Journal of Kidney Diseases 42:5, 906-925
CrossRef223
Julie A Johnson. (2003) Pharmacogenetics: potential for individualized drug therapy through genetics. Trends in Genetics 19:11, 660-666
CrossRef224
Colleen E Clancy, Robert S Kass. (2003) Pharmacogenomics in the treatment of epilepsy. Pharmacogenomics 4:6, 747-751
CrossRef225
Guttmacher, Alan E., Collins, Francis S., . (2003) Welcome to the Genomic Era. New England Journal of Medicine 349:10, 996-998
Full Text226
Bernhard Schaller, Stephan J. Rüegg. (2003) Brain Tumor and Seizures: Pathophysiology and Its Implications for Treatment Revisited. Epilepsia 44:9, 1223-1232
CrossRef227
Ingrid E. Scheffer, Samuel F. Berkovic. (2003) The genetics of human epilepsy. Trends in Pharmacological Sciences 24:8, 428-433
CrossRef228
Mayssa Attar, Vincent HL Lee. (2003) Pharmacogenomic considerations in drug delivery. Pharmacogenomics 4:4, 443-461
CrossRef229
Toshiyuki Sakaeda, Tsutomu Nakamura, Katsuhiko Okumura. (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:4, 397-410
CrossRef230
Pedley, Timothy A., Hirano, Michio, . (2003) Is Refractory Epilepsy Due to Genetically Determined Resistance to Antiepileptic Drugs?. New England Journal of Medicine 348:15, 1480-1482
Full Text231
D.B. GOLDSTEIN, G.L. CAVALLERI, K.R. AHMADI. (2003) The Genetics of Common Diseases: 10 Million Times as Hard. Cold Spring Harbor Symposia on Quantitative Biology 68:1, 395-402
CrossRef
